PreventAGE Health Care, LLC

Company Profile

Industry Sector: Health care, clinical laboratory, biomarkers

Company Overview: PreventAGE Health Care, LLC employs precision bioanalytical technologies and algorithms to alert patients with diabetes to their personal risk for developing specific complications. Our report, Compass™ (Complications Propensity Assessment), will be used by physicians and patients to predict risk, personalize treatments, improve outcomes, and reduce healthcare costs.

Target Market(s):
1. Diabetes Centers of Excellence
2. Concierge Medical Practices
3. Integrated Health Care Delivery Systems
4. Specialists – Endocrinologists
5. Primary Care Physicians
6. Patients

Key Value Drivers

Technology: PreventAGE operates a central clinical laboratory that analyses blood and urine samples from patients with diabetes. State-of-the-art mass spectrometry and proprietary methods are used to precisely identify and quantitate selected biomarkers, Advanced Glycation End Products (AGEs) and Oxidation Products (OPs), which correlate with specific complications secondary to diabetes.

Competitive Advantage: The company has developed patented methods and proprietary analytics to produce its Compass™ risk report. Moreover, the company has the world’s most comprehensive and clinically validated data base of AGEs and OPs from patients with diabetes.

Plan & Strategy: Drive adoption through convincing demonstration that knowing an individual’s own risk propensity to develop complications results in improved outcomes. Collaborate with Diabetes Centers of Excellence and other early adopters to increase awareness and generate interest.

Contact: Mark J. Carvlin, PhD
President & Chief Operating Officer
Tel: 908-812-2924

Location: Dartmouth Regional Technology Center
Lebanon, NH

Website: http://www.preventagehealthcare.com

Email: mcarvlin@preventagehealthcare.com
Management

Leadership:
Paul Beisswenger, MD
Founder and Chief Scientific Officer

Paul is an Endocrinologist and Emeritus Professor of Medicine at the Geisel School of Medicine at Dartmouth. He has directed a productive research program over 40 years at the University of Pennsylvania and Dartmouth, investigating the biochemical basis of diabetic complications. At PreventAGE, his focus is on new biomarkers that provide early detection and the treatments to prevent and reverse them. His research has combined studies of human populations with powerful analytic laboratory techniques to address some of the important outstanding questions regarding diabetic complications. Dr. Beisswenger also maintained a clinical practice for 37 years, with a major focus on diabetes and was named to the "Best Doctors in America" list by Woodward-White. He has been an active member of the American Diabetes Association and has been on its National Board of Directors and a number of major national committees. At Dartmouth he served as chairman of Endocrinology and Metabolism, and directed several major academic courses as well as educating health care professionals on a national and international level.

Mark Carvlin, PhD
President and Chief Operating Officer

Mark is a seasoned veteran of the life sciences industry serving as an entrepreneur, venture capitalist, consultant, and executive. Recently, he has served as Chief Executive Officer (CEO) Nanoscan Imaging, Chief Operating Officer (COO) of CardioVax, and Vice President, Clinical Affairs for Aterochem. Mark held positions of Venture Partner and General Partner in Mi3 Venture Partners, a venture capital fund pursuing early-stage investments in life science technologies. In addition, he is a founding partner in SWGC Life-Sciences, a strategic management consulting company. Before pursuing entrepreneurial activities, Mark spent 10 years in the pharmaceutical industry advancing in business development, clinical development, strategic management, marketing, medical

Product Pipeline

1. Pipeline One: Available Currently
Advanced glycation end products – soluble fraction.
Oxidation products

2. Pipeline Two: Available H1 2017
Advanced glycation end products – protein-bound fraction

3. Pipeline Three: Available H1 2018
Receptor for advanced glycation end products (RAGE)
services and planning, and government and business affairs with Bracco Diagnostics Inc. and Bristol-Myers Squibb. Dr. Carvlin has been a member of the Radiology Departments of Georgetown University and the University of Pennsylvania. He has served as the principal investigator on a number of Phase 2, Phase 3, and Phase 4 clinical trials and has co-authored over 125 scientific publications. Dr. Carvlin received his Ph.D. in Biophysics from Roswell Park Cancer Institute.

**Scientific Advisory Board:**

**John W. Baynes, PhD,** is the Carolina Distinguished Professor Emeritus, at the University of South Carolina, School of Medicine, Department of Pharmacology, Physiology and Neuroscience. Dr. Baynes has held many positions in his career and has earned many awards and accolades for his work as a researcher, teacher, administrator and thought leader. He is an expert known for his pioneering work in investigating the role of glycation of proteins and subsequent Maillard reactions of glycated proteins in the development of pathology in diabetes and aging.

**Alan J. Garber, MD, PhD, FACE,** is Professor in the Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology at Baylor College of Medicine. Dr. Garber has served on the boards of numerous organizations including the American Diabetes Association and the American Association of Clinical Endocrinologists. He routinely consults for the NIH, the National Heart, Lung and Blood Institute, the American Heart Association, and the National Kidney Foundation. Dr. Garber has served as the editor of Clinical Diabetes and he is currently the editor of Diabetes, Obesity and Metabolism.